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4.1 INTRODUCTION TO DIABETES MELLITUS 
 
4.1.1 The Conditions 
 
Diabetes Mellitus is not a single disorder but a heterogeneous group of disorders.  All forms of 
diabetes mellitus are characterized by hyperglycemia and disturbances of carbohydrate, fat and 
protein metabolism which are associated with absolute or relative deficiencies of insulin action 
and/or insulin secretion. The World Health Organization (WHO)  in 1985 developed a now 
widely accepted classification of the disorder, largely based on clinical characteristics (see table 
1) (WHO Study Group on Diabetes Mellitus, 1985).  
 
Insulin is needed to allow glucose to pass from the blood into most of the body cells. Only the 
cells of the brain and central nervous system can use glucose from the blood in the absence of 
insulin. Without insulin,  most body cells metabolize substances other than glucose for energy. 
However, fat metabolism in the absence of glucose metabolism, creates ketone bodies which are 
poisonous and their build up is associated with hyperglycemic coma. In the absence of sufficient 
insulin, unmetabolized glucose builds  up in the blood. Water is drawn from body cells by 
osmosis to dilute the highly concentrated blood, and is then excreted along with much of the 
glucose, once the renal threshold for glucose (usually 10mmol/L) is exceeded. Dehydration 
follows.  
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The characteristic presenting symptoms of diabetes are fatigue, extreme thirst, excessive 
urination, unexplained itch, recurrent infections (e.g. boils and thrush) and otherwise 
unexplained weight loss. These symptoms recur if treatment is not adequately controlling the 
condition.  
 
Complications of diabetes are responsible for considerable morbidity and mortality. The acute 
complications of diabetes are hypo- and hyperglycemic coma and infections. The chronic 
complications include microvascular complications such as retinopathy and nephropathy, and the 
macrovascular complications of heart disease and stroke. Diabetes mellitus is the commonest 
cause of blindness and of renal failure in the UK and the USA. Other common complications 
include autonomic and peripheral neuropathy. A combination of vascular and neuropathic 
disturbances result in a high prevalence of impotence in men with diabetes. Peripheral 
neuropathy causes lack of sensation in the feet which can cause minor injuries to go unnoticed, 
become infected and, with circulatory problems obstructing healing, ulceration and gangrene are 
serious risks and amputation is not uncommon.  Recent evidence from metaanalysis of studies of 
the relationship between glycemic control and microvascular complications (Wang, Lau & 
Chalmers, 1993), and from the longitudinal multi-centre Diabetes  Control and Complications 
Trial in the USA (DCCT Research Group, 1993), have established a clear relationship between 
improved blood glucose control and reduction of risk of retinopathy and other microvascular 
complications in IDDM. It is likely that there would be similar findings for NIDDM though the 
studies did not include NIDDM patients. However, the DCCT included highly selected, well-
motivated, well-educated and well-supported patients, cared for by well-staffed diabetes care 
teams involving educators and psychologists as well as diabetologists and diabetes specialist 
nurses.  
 
The challenge of obtaining the goals of the intensively treated patients in the DCCT with the vast 
majority of people with diabetes given the more limited health care resources typically available 
in routine practice, is considerable. If diabetes control can be improved without significant 
damage to quality of life the economic, health and quality of life savings associated with a 
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reduction in complications in later life will be vast. Although some people who have had poorly 
controlled diabetes over many years do not develop complications,  complications commonly 
arise after 15-20 years of diabetes and  individuals in their 40's or even 30's may develop several 
complications in rapid succession. However, 15 years ago patients had no way of monitoring 
their own blood glucose levels at home. Urine glucose monitoring only told them when their 
blood glucose had exceeded the renal threshold of approximately 10mmol/L (i.e. was far too 
high), without being able to discriminate between the too high levels of  7-10 mmol/L or the 
hypoglycemic levels below 4mmol/L. Clinics relied on random blood glucose testing and there 
were no measures of average blood glucose over a longer period. Now there are measures of 
glycosylated hemoglobin (GHb or HbA1 or HbA1c) which indicate average blood glucose over a 
6 to 8 week period and measures of glycosylated protein, fructosamine, which indicates average 
blood glucose over a two week period. Blood-glucose meters for patients were first introduced in 
the early 1980s and the accuracy and convenience of the meters and the reagent strips they use 
has improved dramatically since the early models. Now blood-glucose monitoring is part of the 
daily routine for most people using insulin in developed countries. Blood-glucose monitoring is 
less often prescribed for tablet- and diet-alone-treated patients, financial reasons probably being 
allowed to outweigh the educational value of accurate feedback in improving control long term. 
The reduced risk of hypoglycemia and diabetic keto-acidosis in NIDDM patients not using 
insulin means that acute crises rarely arise in these patients though their risk of long-term 
complications is at least as great as in IDDM and might be expected to be reduced if feedback 
from blood-glucose monitoring were provided.  
 
4.1.2 Insulin Dependent Diabetes Mellitus (IDDM) 
Insulin-dependent diabetes mellitus (IDDM), also known as juvenile-onset diabetes, ketosis-
prone diabetes, or Type 1 diabetes, is the commonest form of diabetes in children and young 
adults of European origin. Age at clinical onset of the condition is usually under the age of 30 
years. 
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People who develop IDDM lose the ability to produce insulin altogether. Diagnosis and 
treatment with exogenous insulin is often followed by a 'honeymoon' period when endogenous 
insulin production restarts and the exogenous insulin doses required are reduced and, 
occasionally, can be discontinued. This is, however, always only a temporary respite. Thereafter, 
exogenous insulin, usually delivered by subcutaneous injection, will be needed continuously 
throughout the lifetime of a person with IDDM. If insulin therapy is discontinued, even for a few 
days, ketotic coma will develop and, if not treated, will result in death. 
 
The onset of IDDM is abrupt, with severe thirst, excessive urination and dramatic weight loss. 
Individuals usually present to the doctor with one or more of these symptoms and an elevated 
blood glucose level.  They will also have glucose, and possibly ketones, in their urine. This 
combination indicates diabetic keto-acidosis and is a potentially fatal medical emergency. 
Diagnosis is made clinically and confirmed on the basis of an elevated blood glucose 
concentration (>6.7mmol/L). 
 
IDDM can be managed by balancing injected insulin, carbohydrate intake, and energy 
expenditure. The goal of treatment is to maintain blood glucose levels as close to the normal 
range as possible (i.e. 4-6mmol/L) in order to reduce the risk of chronic complications, while 
also avoiding the dangers of blood glucose levels falling to hypoglycemic levels. To achieve this 
goal, people with IDDM will usually need to measure their blood glucose levels several times 
daily. In the 1980's and early 1990's, two injections a day were commonly used by IDDM 
patients. However, recent evidence has shown that more intensive therapy, with up to five 
injections per day, is associated with reduced risk of chronic complications (DCCT Research 
Group, 1993; Wang et al. 1993) though at the price of three-fold increases in occurrence of 
severe hypoglycemic episodes (DCCT). Intensive insulin regimens have become more 
commonly used in the 1990s and this trend has been facilitated by the development of insulin 
delivery devices such as pen-injectors which simplify the task of administering insulin, and 
continuing improvements in blood glucose monitoring methods (Bradley, Christie & Home 
[Eds.], 1991) The dangers of hypoglycemia, which tend to be increased with the intensity of the 
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insulin therapy, give increasing cause for concern. Severe hypoglycemic episodes cause acute 
behavior changes with behavior often becoming aggressive, and unless action is taken to increase 
the blood glucose levels, collapse and coma follow rapidly. Insulin-dependent individuals need 
to carry with them at all times glucose tablets or some other form of rapidly absorbed glucose so 
that they can respond to early signs of hypoglycemia by increasing their blood glucose levels and 
thus prevent a severe hypoglycemic episode.    
 
 
4.1.3 Non-insulin Dependent Diabetes Mellitus (NIDDM) 
 
Non-insulin-dependent diabetes mellitus (NIDDM), also known as maturity-onset diabetes or 
Type 2 diabetes, is the commonest form of diabetes world-wide (85% of cases in the developed 
world). Age at clinical onset of the disorder is usually over the age of 40 years. 
 
People with NIDDM continue to produce insulin, but it is inadequate either in amount or in 
action to maintain their blood glucose levels in the normal range. With the development of the 
pathological process involved, patients first have asymptomatic glucose intolerance and then go 
on to develop diabetes mellitus. Unlike IDDM, the process of development of NIDDM is 
insidious. Individuals may have NIDDM for years before it is diagnosed.  
 
Diagnosis may result from patients presenting with classical symptoms, or with one or more of 
the complications of diabetes, or diabetes may be found on routine medical examination 
(confirmed by oral glucose tolerance testing). Dietary management is the first choice of treatment 
for NIDDM.  A low fat weight-reducing high fiber diet will be recommended to those who are 
overweight and if weight can be reduced and maintained close to ideal weight it may be the case 
that no further treatment is required.  The diet recommended is usually high in complex 
carbohydrates and fiber and low in refined carbohydrates in order to avoid rapid absorption of 
glucose and to maintain blood glucose at a more even level without peaks of hyperglycemia.  
Reduction in fats may also be recommended (particularly if the individual has abnormal lipid 
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levels) with a view to lowering and maintaining triglyceride and cholesterol levels and thereby 
reducing the risks of cardiovascular disease which accompany NIDDM.  
 
If glucose levels cannot be controlled adequately with diet alone, oral hypoglycemic agents are 
added to treatment. These tablets do not contain insulin which, being a protein, would be 
digested if taken orally, but rather act to stimulate production of endogenous insulin or to 
enhance the effectiveness of existing levels of insulin. A variety of oral hypoglycemic drugs are 
available, such as sulphonylureas and biguanides. These differ in their modes of action and side 
effects, for example, sulphonylureas may increase the risk of hypoglycemia. If adequate control 
of blood glucose cannot be achieved with diet and tablets, insulin is likely to be recommended. It 
is important to recognize that NIDDM patients using insulin are just as prone to severe 
hypoglycemia as IDDM patients. However, because in NIDDM there is limited endogenous 
insulin secretion, sufficient to allow some glucose metabolism, ketoacidosis and hyperglycemic 
coma are unlikely to develop if exogenous insulin is reduced or discontinued. 
 
Although NIDDM is often misguidedly referred to as 'mild diabetes', the risk of chronic 
complications is no less than that associated with IDDM. People with NIDDM are two or three 
times as likely to develop cardiovascular disease than people without diabetes and 75% die of 
cardiovascular disease. The life expectancy of people with NIDDM is, on average, reduced by a  
decade as a result of the disease. Although the later onset of NIDDM might be expected to 
reduce the risk of complications which are usually associated with raised blood glucose levels 
over 15 or more years, the insidious onset of NIDDM delays diagnosis, and chronic 
hyperglycemia over many years probably accounts for the many cases which are only diagnosed 
after the onset of complications.  
 
 
 4.2.IDDM: ETIOLOGY, RISK FACTORS AND PREVENTION  
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IDDM is caused by the autoimmune destruction of insulin-producing beta-cells in the pancreas. 
The pathological process is probably initiated several years, sometimes even decades, before 
clinical onset by an interaction of genetic predisposition and environmental triggers (Zimmet, 
1995).  The incidence of IDDM has been reported to change with age, rising to a peak around 
puberty (Laakso & Pyörälä, 1985) with a second peak later in life (Krolewski, Warram, Rand & 
Kahn, 1987). Altogether more cases of IDDM are diagnosed in adulthood rather than in 
childhood (Vandewalle et al.1993) and, in some studies, a higher incidence has been found in 
males than in females (Blohmé et al. 1992;  Bruno et al.1993). Marked geographical variation in 
IDDM incidence has been observed, varying from 35.3 per 100,000 inhabitants in Finland to 1.9 
per 100,000 in Japan (Karvonen, Tuomilehto, Libman &  LaPorte, 1993). Differences in 
incidence between neighboring countries have led to the assumption that diet and lifestyle are 
important determinants of the disease (Green, Gale & Patterson, 1992), but differences in the 
frequency of 'diabetogenes' may also play a role. Over the past 20 years the incidence of IDDM 
has doubled in Europe (Bingley & Gale, 1989) and is steadily increasing worldwide (Krolewski 
et al, 1987). However, most of the incidence data are only available for those with early onset 
before the age of 20 years. Since most cases are diagnosed during adulthood, it may be that the 
apparent doubling in incidence is due to a shift towards earlier clinical onset of diabetes rather 
than to an increase in the number of people developing IDDM at some point in their lives 
(Bingley & Gale). 
 
4.2.1. Risk Factors in IDDM 
 
A genome-wide search has revealed that more than 12 gene loci contribute to genetic 
susceptibility for IDDM (Todd, 1995). The genetic component of the condition is indicated by 
the 5% prevalence of IDDM in first degree relatives, compared with less than 1% in the general 
population (Bingley, Bonifacio & Gale, 1993; Gorus, Anselmo & Keymeulen, 1993), and the 
higher concordance rate for IDDM in identical than in non-identical twins (Leslie & Elliott, 
1994) Nevertheless, 90% of the new cases occur in individuals without a family history of 
diabetes (Bingley et al.). These individuals, however, also carry certain predisposing genotypes. 
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Genetic susceptibility is not sufficient to cause diabetes (Karvonen et al. 1993) since a majority 
of people with disease-associated alleles do not develop IDDM. Environmental agents appear to 
have an important role. The way in which the environment affects the pathogenesis is still 
unclear. It has been hypothesized that viral infection (Krolewski et al. 1987; Zimmet, 1995) and 
proteins in the diet (Gerstein, 1994) are important factors. Psychological stress may also have a 
role in increasing vulnerability to viral infection or impairing defense mechanisms against such 
infection, thereby facilitating the progression of the hidden pathological process. Clear evidence 
for such an effect is difficult to obtain though suggestive evidence is available to support the 
notion that stress may contribute to the development of IDDM (see Bradley, 1988 for review). 
There is stronger evidence to suggest that psychological stress can trigger the onset of symptoms 
in a person in whom islet beta-cell damage is at an advanced stage (Bradley, 1988; Clayer, 
Bookless-Pratz & Harris, 1985). Blood glucose levels already raised as a consequence of 
diminishing insulin production can be further elevated by neuroendocrine responses to 
psychological stress and tipped over the renal threshold to precipitate the overt symptoms of 
diabetes which would have appeared in due course without the occurrence of the stress.  
 
Current knowledge about the incidence of IDDM has developed as a result of national and 
regional registries (Karvonen et al. 1993). Standardized data are collected on previous exposure 
to environmental factors and occurrence of metabolic and genetic markers for new IDDM cases 
(Gorus et al. 1993). The long-term follow-up of at-risk families allows comparative studies of the 
cause and pathogenesis of the disease and can help clarify temporal, regional and environmental 
variations in the incidence of diabetes (Diabetes Epidemiology Research International Group 
[DERIG],1988).  
 
4.2.2. Prevention of IDDM 
 
Presently, there is no cure for IDDM. Despite evidence that improved blood glucose control 
reduces the risks of complications and despite the development of increasingly effective insulins 
and more convenient delivery systems and monitoring devices, the complications of diabetes 
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continue to present major health problems with massive personal, social and economic costs. The 
possibilities of preventive strategies are therefore attracting considerable attention. 
 
4.2.2.1. Primary prevention 
The aim of primary prevention is to avoid the initiation of the hidden pathological process 
leading to IDDM. This strategy requires identification of genetically predisposed individuals and 
protection against avoidable environmental factors (e.g. nutritional or viral). Because of the 
current lack of specific knowledge about the nature of these triggering factors, large-scale 
initiatives could lead to treatment of many people who might never develop IDDM (Palmer & 
McCulloch, 1991). The role of the diabetes registries is crucial in improving understanding of the 
interaction between genetic and environmental factors. A first attempt at primary prevention has 
been initiated in Finland (Akerblom et al.1993), where the role of cows' milk proteins in the diet 
of young children is under investigation.   
 
4.2.2.2. Secondary prevention 
The preclinical phase of IDDM is accompanied by humoral, immune and metabolic 
abnormalities. During the past decade, much knowledge has been accumulated about the 
diabetes-predictive value of several of these early markers (Dotta, Dionisi, Farilla & DiMario, 
1996). Refining the use of these marker combinations would allow early diagnosis of diabetes 
and offers the possibility of secondary prevention with the aim of halting or delaying the 
progression of further destruction of the beta-cell mass by pharmacological intervention at an 
early stage of the pathological process.   
 
The presence of antibodies against various diabetes-associated islet-cell autoantigens is currently 
considered to be one of the best indicators of a latent autoimmune disease process in the islets 
(Dotta et al. 1996), although the relation of these antibodies to the pathological changes is 
presently poorly understood. Data obtained in a representative sample recruited through diabetes 
registries show that at least one of these immunological markers is present in approximately 90% 
of the individuals at clinical diabetes onset and also in the vast majority of relatives in the 
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preclinical stage (Gorus et al.[in press]; Verge et al.1996). The presence of more than one type of 
autoantibody greatly increases the risk of IDDM (Eisenbarth, Verge, Allen & Rewers, 1993). 
Metabolic markers can be detected in a later phase of the preclinical stage. A decreased early-
insulin response to an intravenous glucose challenge and increased proinsulin levels can indicate 
impending clinical onset of IDDM. There are now indications that combined presence of these 
biological markers can also be helpful in identifying preclinical IDDM in the general population 
(Hagopian et al.1995). The early diagnosis of a hidden disease process now creates the 
theoretical possibility of influencing the process pharmacologically in such a way that the 
clinical disease manifestation is prevented. Pilot studies in animal models and on a small scale in 
humans suggest that such an approach is feasible. Large-scale intervention trials have been 
initiated with nicotinamide and with insulin. It is expected from preliminary studies that 
nicotinamide (vitamin B3) could delay the onset of IDDM (Elliott & Chase, 1991; Pozzilli & 
Andreani, 1993), but that the preventive effect could vary from individual to individual 
(Herskowitz, Jackson, Soeldner & Eisenbarth, 1989). Multi-centre programs were launched to 
investigate the effect of this vitamin on the pathological process and on the biological markers in 
first degree relatives (Nordenfelt, 1996). A second approach has been the prophylactic use of 
insulin to allow the remaining beta-cell mass to rest or to induce tolerance against beta-cell 
autoantigens. A clinical trial has begun in the USA (Keller, Eisenbarth & Jackson, 1993). 
 
4.2.2.3. Tertiary prevention 
Tertiary prevention aims to prevent long-term complications despite the onset of diabetes. One 
approach has been pancreatic organ transplantation which has been shown to restore 
normoglycemia and to halt the progression of chronic complications (Robertson, 1992). 
However, the intervention is by no means a cure, and the required immunotherapy can cause 
serious unwanted effects, including increased risk of cancers. For these reasons, solitary pancreas 
transplantation is not a suitable treatment for diabetes. Pancreas transplantation is, however, 
sometimes performed in combination with a kidney graft in individuals with severe chronic 
complications. Over the last 20 years, transplantation of insulin producing islets has been studied 
as an alternative for pancreatic organ transplantation (Pipeleers, Keymeulen & Korbutt, 1994). 
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Several clinical trials have been initiated worldwide (Sutherland et al.1996). Although many 
obstacles have yet to be overcome, transplantation of allogeneic (including human to human) or 
xenogeneic (including pig to human) donor tissue has the potential to treat IDDM in the early 
stages with a view to avoiding complications (Pipeleers et al).  
 
 
4.3. NIDDM: ETIOLOGY, RISK FACTORS AND PREVENTION 
 
4.3.1. Risk Factors in NIDDM 
 
NIDDM appears to be a complex multigenic-environmental disorder, with a strong genetic 
component. Current theories about its pathogenesis implicate intrauterine malnutrition (Hales & 
Barker, 1992) and a common (as yet little understood) metabolic disorder Syndrome X  (Reaven, 
1988) which leads in differing circumstances to NIDDM, obesity, hypertension, or 
hyperuricaemia (gout). 
 
Familial clustering is a characteristic feature of NIDDM. Monozygotic twin studies show a 
concordance rate of over 90% (Newman et al.1987; Pyke, 1979). The US National Health and 
Examination Survey (Harris, 1984) showed that in people aged 35 to 74, about 35% of those with 
a medical history of diabetes had one or both parents with diabetes. Other studies have shown an 
even greater concordance for NIDDM in sibling pairs than parents and children (Beaty, Neel & 
Fajans, 1982). The literature on risk of NIDDM in the offspring of affected people has been 
reviewed by Pierce and colleagues (Pierce, Keen & Bradley, 1995). They concluded that having 
a parent with NIDDM increases offspring risk by between two- and four-fold, but a family 
history of NIDDM does not increase risk of IDDM. NIDDM risk increases if the affected parent 
is the mother rather than the father, or if both parents are affected, and with increasing age, and 
in certain racial groups.  
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NIDDM is more common in those who are overweight, people who take little exercise, and in 
racial groups other than Northern European Whites. The association between obesity and risk of 
NIDDM is strong, graded, and consistent. This literature has been comprehensively reviewed by 
Felber, Acheson and Tappy (1992). The distribution of obesity, central or peripheral, has been 
shown to be a better predictor of later diabetes than the degree of adiposity. People with 'central' 
or 'male' type obesity are at much higher risk than those with 'peripheral' obesity. 
 
Epidemiological studies have shown a relationship between inactivity and NIDDM (Helmrich, 
Ragland, Taylor, Leung & Paffenbarger, 1991; Taylor, Ramm, Zimmet, Raper & Ringrose, 
1984), although these studies have been cross-sectional rather than prospective and hence 
caution is needed in deducing causality. 
 
People with impaired glucose tolerance progress to NIDDM at a rate of between 2% and 6% per 
year, largely dependent on race (Jarret, Keen, Fuller & McCartney, 1979; Saad et al.1988). 
However, it is not yet possible to predict who will progress to NIDDM and who will revert to 
metabolic normality. Gestational diabetes can be regarded as an extreme form of impaired 
glucose tolerance in some pregnant women in response to the metabolic strain of pregnancy. 
After the baby is born, the diabetes may disappear, but it is likely to reappear in later life. 
 
Certain racial groups, including Micronesians (e.g. Nauruans), Native Americans (e.g. Pimas), 
Asian Indians, Mexican Americans, and Australian Aborigines, seem to be particularly prone to 
NIDDM, a fact which may be due to their genotype (Neel, 1982). Their susceptibility manifests 
itself when they move from a 'traditional' lifestyle to a more 'modern' one with increased 
availability of food and with reduction in the demand for physical exertion (Zimmet, 1992). 
Possibly, the genetic make-up of these people is adapted to survival in the face of variable 
supplies of food. This 'thrifty genotype'  (Neel, 1982) lays down fat stores very quickly when 
food is available and so facilitates survival during periods of famine. Such a genetic make-up 
would have clear evolutionary advantages in a 'traditional' lifestyle such as that of the Australian 
Aboriginal hunter-gatherers. However, when these people move to a life-style characterized by a 
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continuously plentiful food supply, they readily become overweight and develop NIDDM. 
Alternatively Hales and Barker (1992) have hypothesized that infants who are malnourished in 
utero, develop physical changes in their pancreas and other organs, which in later life cause a 
decreased ability to cope with excess calories and so these people become overweight and 
develop NIDDM. This 'thrifty phenotype' hypothesis could also account for these racial groups 
being particularly prone to NIDDM in the face of westernization. 
 
 
4.3.2. Prevention of NIDDM 
 
4.3.2.1. Primary prevention 
There have been several studies testing the possibility of primary prevention of NIDDM using  
either pharmaceutical agents or behavioral methods  (Erikksonn & Lindegarde, 1991; Jarret et al, 
1979; Keen, Jarret & McCartney, 1982; Knowler, Sartor & Schersten, 1987; Sartor, Schersten, 
Carlstrom, Melander & Persson, 1980;). These have given somewhat contradictory results. 
However, recently Pan et al. (1994) reported the results of a randomized controlled trial of diet 
and exercise alone, or in combination, suggesting that all of these interventions reduced the rate 
of progression to NIDDM in people with impaired glucose tolerance in mainland China. In the 
light of these findings, a large multi-centre primary prevention trial is being planned in the USA. 
The interventions are likely to include hypoglycemic drugs and/or behavioral methods aimed at 
the reduction of obesity and the promotion of exercise. The challenges of designing such a trial 
are considerable as potential recruits are likely to have preferences for drug or lifestyle 
intervention which will make a simple randomized controlled trial design inappropriate (Bradley, 
1993).  
 
4.3.2.2. Secondary prevention 
The secondary prevention of NIDDM is currently under investigation by the UK Prospective 
Diabetes Study Group (UKPDS) who are investigating the effects of early treatment regimens for 
NIDDM (UK Prospective Diabetes Study Group VIII, 1991).  
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4.3.2.3. Tertiary prevention 
Tertiary prevention of NIDDM involves the detection and treatment of complications of 
NIDDM, and the reduction of associated risk factors. Retinopathy (American Diabetes 
Association, 1992), neuropathy, and early signs of nephropathy (Viberti, Walker & Pinto, 1992) 
can be detected by annual screening. Retinopathy can usually  be treated effectively by laser 
therapy to prevent progression to blindness if detected in the early stages (Diabetic Retinopathy 
Study Group, 1981). Treatment of established neuropathy has been described by the St. Vincent 
Guidelines as 'unsatisfactory' (Krans,  Porta,  Keen & Staehr Johansen, 1995), though there is 
evidence from the DCCT that improved blood glucose control reduces risk of nerve damage 
(DCCT research group, 1993). There has been considerable interest in the possibilities of using 
drugs, particularly aldose reductase inhibitors, as neuropathy prevention therapy, though their 
value is far from clear (Krans et al.). The St. Vincent Guidelines suggest that the best hope for 
preventing neuropathic foot problems developing is through the education of patients and 
professionals and the organization of foot care services (Krans et al.).  Incipient nephropathy can 
be detected by testing the urine for small amounts of albumin (microalbuminuria), and at this 
stage the process is potentially reversible by improved management of blood pressure and 
metabolic control. Avoidance of smoking (Mulhauser, 1990) and reduction of any modifiable 
risk factors for cardiovascular disease is particularly important for people with NIDDM, because 
of their elevated risk of myocardial infarction and stroke.  
 
As with IDDM, psychological stress may trigger the manifestation of symptoms in NIDDM 
probably by a similar mechanism  (Bradley, 1988; Clayer et al.1985). Evidence for a causal role 
of stress in initial onset of the pathological process is again less clear. Mechanisms by which 
stressful events may play a causal role will vary depending on the kind of NIDDM where, unlike 
IDDM, there is not always a reduction in insulin production. Indeed in individuals with NIDDM 
who are not overweight, insulin resistance may be involved where insulin production may 
increase as its effectiveness decreases. There is some evidence to suggest that stressful events 
may be causal in the onset of insulin resistance with stress-induced increases in adrenaline and 
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cortisol secretion reducing the effectiveness of an individual's insulin (Rizza, Mandarion & 
Gerich, 1982; Smith, 1984). If repeated or prolonged stressful events are experienced, insulin 
resistance over a period of months or years may result in excessive compensatory insulin 
production and, eventually, to exhaustion of pancreatic islet cells and manifestation of diabetes. 
 
 
4.4 IMPACT OF THE CONDITION ACROSS THE LIFE SPAN ON PERSON AND FAMILY  
 
With increasing knowledge of the familial risks of diabetes, diabetes may have a psychological 
impact on the outlook on life of an at-risk individual well before onset or without the actual onset 
necessarily occurring. People with diabetes may be concerned about the possibilities of onset of 
diabetes in their children. Indeed, the fact that a proportion of parents of at-risk children are 
prepared to enter them in clinical trials of the use of daily insulin injections in the hope of 
preventing diabetes onset (Keller et al.1993) provides an indication of the level of concern and 
lengths to which some are prepared to go in order to reduce the risk of diabetes onset.  
 
When diabetes is diagnosed, the demands of diabetes and its treatment vary considerably with 
the type of diabetes (IDDM usually being more demanding in terms of insulin treatment required 
and the increased need for monitoring of blood glucose levels). Within any one type of diabetes 
there is considerable individual variation in the effort needed and difficulty experienced in 
achieving blood glucose levels which approximate normoglycaemia. The need to manage 
diabetes  can add to the psychological demands of meeting the commonly experienced 
challenges throughout the life-cycle, such as leaving home, marriage, and pregnancy. Pregnancy, 
and preparing for pregnancy, are especially demanding times for women with diabetes when the 
need for normoglycaemia is emphasized as essential for the health of the baby and recommended 
prior to conception through to birth. The success which many women achieve in obtaining near-
normal blood glucose levels at this time is sometimes attributed by their physicians to the 
hormonal changes of pregnancy rather than to the efforts of the woman herself. Such attributions 
can be demotivating and depressing. The challenges of a first pregnancy are, however, dwarfed 
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by the challenges of a second pregnancy where the needs of the first child are often incompatible 
with the needs of the developing second child. Pregnant women with diabetes attempting to 
achieve normoglycaemia are particularly prone to hypoglycemia and this risk carries new 
dangers when the pregnant woman is also in sole charge of a young child. Fear of hypoglycemia, 
a concern to most people with insulin-requiring diabetes (Irvine, Cox & Gonder-Frederick, 1994) 
is likely to be heightened in pregnant women, especially those with young dependent children. 
 
Many people with insulin-requiring diabetes are sufficiently fearful of hypoglycemic reactions  
to avoid tight control of blood glucose levels and the associated increase in risk of hypoglycemia 
especially if their warning signs of hypoglycemia are unreliable (see sections below on 
psychological aspects of symptoms and on Blood Glucose Awareness Training). Fear of 
hypoglycemia may lead individuals to aim for higher blood glucose levels which increase their 
risk of long-term complications. Others, anxious to reduce their risks of other complications may 
be experiencing numerous, potentially dangerous, hypoglycemic episodes.  
 
When NIDDM patients are unable to achieve adequate diabetes control with tablets and diet, it is 
usually recommended that insulin be introduced. Indeed the prospect of insulin injections is often 
used by doctors as a stick to motivate greater dietary efforts and more reliable use of 
sulphonylurea tablets. As a result, the need for insulin may be taken as a sign of failure or a sign 
of progression from 'mild' to increasingly 'severe' diabetes. Many patients also fear the process of 
injection, prior to the experience. In practice, the injections are usually found to be an obstacle 
soon overcome and incorporated into daily life with little difficulty. Injections allow greater 
flexibility of timing and content of meals as well as improved blood glucose control. Improved 
satisfaction with treatment following changeover from tablets to insulin has been found in 
several studies (Jennings et al. 1991; Taylor, Foster, Kyne-Gzebalski & Vanderpump, 1994). 
Such findings could be used by health professionals to inspire their patients who are reluctant to 
change. Interestingly the aspect of quality of life widely felt by people with diabetes to be  
impaired by their diabetes and rated as very important, is enjoyment of food (Bradley, 1995a). 
After decades of attempting to persuade patients to modify the timing and content of their food 
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intake to fit in with fixed insulin doses, and to use food manipulation to compensate for changes 
in energy expenditure, there is now growing recognition that a more rewarding approach is to 
manipulate insulin doses to fit in with food and other lifestyle factors (Howorka, 1996).  
 
4.5. PSYCHOLOGICAL ASPECTS OF SYMPTOMS 
 
Individual variation in the nature and extent of symptoms of hypoglycemia is considerable. 
Symptoms may include autonomic symptoms such as irritability or anxiety, shaking or sweating 
associated with adrenaline released in response to the falling blood glucose level. Symptoms may 
also include neuroglycopenic symptoms such as loss of concentration or memory loss, due to the 
shortage of glucose in the brain (Deary, Hepburn, Macleod & Frier, 1993). Hunger is also a 
common, though by no means universal symptom.  
 
Individuals prone to hypoglycemia include anyone taking insulin and individuals taking certain 
kinds of oral hypoglycemic agent (particularly sulphonylureas). Individuals usually come to 
recognize the idiosyncratic but fairly reliable symptoms which for them herald the onset of 
hypoglycemia, and learn to take action to raise the blood glucose levels before they are rendered 
incapable of doing so by increasingly severe symptoms which impair rational action and precede 
the unconscious state of hypoglycemic coma. However, some individuals lose the ability to 
recognize the symptoms of hypoglycemia and become highly vulnerable to severe hypoglycemia 
as a result. Loss of warning of hypoglycemia, or hypoglycemia unawareness, may result from 
autonomic neuropathy, one of the microvascular complications of diabetes, which becomes 
increasingly common with duration of diabetes of 15 or more years. Damage to the autonomic 
nervous system impairs adrenal responses to low blood glucose levels. In the absence of adrenal 
symptoms, neuroglycopenic symptoms may not be noticed until the cognitive effects are too 
debilitating to take action to raise the blood glucose levels. However, onset of hypoglycemic 
unawareness is not always associated with autonomic neuropathy and there has been much 
concern among people with diabetes, clinicians and researchers to identify the causes of loss of 
warning with a view to preventing this loss or restoring awareness.  
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It has commonly been assumed that hypoglycemic unawareness develops when symptoms of 
hypoglycemia occur below the level of blood glucose at which cognitive impairment begins. It is 
also widely assumed that the detection of hypoglycemia is primarily dependent on autonomic 
symptoms. However, Cox et al. (1994) have argued that neuroglycopenic symptoms, such as 
difficulty in concentrating and lack of coordination, are as prevalent as autonomic symptoms and 
occur at similar levels of blood glucose. Furthermore, people with IDDM have reported using 
neuroglycopenic symptoms to recognize hypoglycemia, sometimes in preference to autonomic 
symptoms. Cox and colleagues  also cited evidence to suggest that an episode of hypoglycemia 
leads to a reduction in strength of autonomic but not neuroglycopenic symptoms associated with 
any subsequent hypoglycemia within 24 hours. In line with these findings are reports from 
elsewhere (Cranston, Lomas, Maran, Macdonald & Amiel, 1994) that neuroglycopenic 
symptoms provided earlier warning of impending hypoglycemia than did autonomic symptoms 
and may indeed be more useful and more reliable cues to low blood glucose than has generally 
been assumed. Cox and colleagues at the University of Virginia have developed a Blood Glucose 
Awareness Training program (Cox, Gonder-Frederick, Julian & Clarke, 1992) which has been 
successfully used to regain lost awareness of hypoglycemia, and Amiel's research group at the 
University of London (Cranston et al.) and others (Fanelli et al. 1993) have also reported success 
using more traditional medical approaches. These interventional approaches are reviewed below. 
 
In the late 1980's there was a nationwide move in the UK to switch from animal insulins 
extracted from cattle and pigs to the genetically engineered 'human' insulin. Most clinicians 
appear to have assumed that the changeover would have little effect on blood glucose levels. 
However, many people with insulin-treated diabetes were profoundly upset by the changeover as 
indicated by the influx of letters to the British Diabetic Association (Posner, 1992). Problems of 
rapid onset of severe hypoglycemia occurring without warning were reported, some with 
devastating and even fatal consequences. Although undoubtedly some of the problems were 
coincidental to the changeover to human insulin, it is by no means clear that all the problems 
would have occurred anyway (Alexander, 1993). The problems were further exacerbated by an 
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unwillingness of some doctors to accept the possibility that human insulin may have caused the 
problems, and their refusal to accede to their patients' requests to change back to animal insulin. 
Many patients continue to suffer from the aftermath of the changeover to human insulin, since 
new developments in insulin delivery systems are usually only developed for use with human 
insulin and thus are not available to those who changed back to animal insulins. The British 
Diabetic Association (BDA) continues to campaign for the provision of animal-insulin 
alternatives to the now standard human-insulin cartridges used in pen-injector devices, so that 
patients using animal insulins may also benefit from the convenience of using these devices 
(North, 1991). 
 
A major reason for anxiety about hypoglycemia is the increasing concern that hypoglycemia may 
lead to chronic forms of cognitive dysfunction. It has long been recognized that severe 
hypoglycemia involving coma can cause chronic impairments of cognitive function. More 
recently, attention has been directed to the chronic effects of less severe, but recurrent 
hypoglycemia (Gold et al. 1994). It is difficult to demonstrate a causal association but the 
available evidence (including uncontrolled case reports and retrospective studies) does suggest 
that repeated and severe hypoglycemia may lead to chronic cognitive dysfunction. Ryan (1994) 
has provided a useful overview of work assessing cognitive impairments related to hypo- and 
hyper-glycemia which assesses the pros and cons of various measures of cognitive function in 
determining the nature and extent of cognitive impairments associated with different levels of 
blood glucose.  
 
In contrast to the marked and troublesome nature of symptoms of hypoglycemia, hyperglycemia 
is quite often asymptomatic and this in itself creates challenges. Indeed some individuals who 
have adapted to raised blood glucose levels feel uncomfortable, when initially reducing their 
blood glucose levels. However, adaptation to the experience of blood glucose levels closer to 
normal levels soon follows. Resistance to tightening control of blood glucose levels may be 
reduced if such patients appreciate that any discomfort is likely to be temporary. 
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Most of the early signs of chronic complications of diabetes are also asymptomatic. High blood 
pressure, microalbuminuria indicative of early signs of kidney problems, and early signs of 
retinal damage are usually, if not always, without symptoms, and require medical screening to 
allow for early diagnosis and treatment. Peripheral neuropathy causes numbness in the 
extremities and a real risk that damage to the feet will go unnoticed. Infections and ulcers, once 
developed can be difficult to clear up in the face of circulatory problems which usually 
accompany the neuropathy and may lead to gangrene and the subsequent need for amputation. 
These serious problems  currently depend for their solution on patient education, vigilant self-
care, and rapid access to skilled chiropody and medical attention when minor damage to the feet 
is first noticed. 
 
 
4.6. SPECIFIC ISSUES OF ADHERENCE 
 
Adherence, or compliance, has been defined as the extent to which a person's behavior coincides 
with health advice (Haynes, Wang & Gomes, 1987). The concept implies that specific 
recommendations can be made which, if followed, are likely to lead to health benefits. Certainly 
the measurement of adherence requires that the recommendations have to be specified, and then 
the extent to which those recommendations have been implemented needs to be assessed. Such 
measurement may be practical if considering whether or not a patient had been adherent in taking 
a course of antibiotics. In this case, the recommendations can be specified in detail and the 
behavior monitored in various ways to establish the extent of match between recommendations 
and behavior. Where diabetes is concerned, potentially effective recommendations are likely to 
be complex, to vary from patient to patient and, for individual patients, to vary from day to day. 
'Simple' recommendations to take the same amount and types of insulin at the same time each 
day and eat the same amount and type of food at the same times to balance that insulin while 
somehow keeping energy expenditure constant are unlikely to be effective in achieving adequate 
diabetes control. If such recommendations did lead to improved metabolic control they would be 
likely to cause serious damage to patients' psychological well-being and quality of life. More 
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complex regimens involve balancing the various manipulable components in the equation (eg 
timing and dose of the next injection of insulin, timing and content of the next meal or snack and 
voluntary exercise) to deal with those components of the equation which are either not 
immediately controllable or cannot be controlled without undesirable costs (e.g. family or work 
commitments, action of the previous insulin injection). Such regimens require sufficient 
education and understanding to allow problem solving appropriate to the occasions that arise and 
cannot be specified in detail in advance.  'Adherence', under these circumstances is an 
unmeasureable and unsuitable concept.  
 
Some authors have referred to measures of diabetes control as 'proxy measures of adherence'. 
Such a practice is highly misleading as it assumes that if the patient had followed whatever 
recommendations had been made then the diabetes control would be maximal. Use of HbA1 or 
other measures of diabetes control as a measure of adherence denies the possibility that the 
recommendations made by  the health professional may have been inadequate to the task of 
controlling that individual's diabetes. There is no good reason to attribute all departures from 
optimal outcomes to patient 'non-adherence' and there are many good reasons for not doing so. In 
particular, it is depressing and discouraging for patients who are trying to deal with the demands 
of diabetes management to have poor outcomes attributed to their actions (or lack of them), 
particularly when they have been struggling to follow recommendations which were not adequate 
to the task. The common tendency to take credit for successes and blame other factors for failure 
is one that affects health professionals as much as other groups (Gamsu & Bradley, 1987; 
Gillespie & Bradley, 1987) and it undoubtedly serves to protect their own self esteem. However, 
such an ego-defensive stance is not only discouraging for patients and their families but also 
serves to reduce the perceived need for interventions to improve the organization and functioning 
of the health-care system (Bradley, 1989). It would be more supportive of patients' self-esteem to 
recognize patients' efforts and achievements  and to adopt a collaborative problem-solving 
approach when outcomes need to be improved.  
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There are many different ways of managing diabetes. If the patient is not able to achieve 
satisfactory diabetes control with one approach, it may be that some aspect of the approach is 
deficient in some way. The education provided for the patient may not have resulted in the 
necessary knowledge and understanding required. Barriers to care may be obstructing application 
of adequate education and may include social pressures and competing demands, fatalistic or 
unrealistically optimistic beliefs about outcomes of diabetes and the risk of complications 
(Glasgow, 1994; Lewis & Bradley, 1994). Knowledge, understanding and beliefs may all be 
compatible with self-care but the recommendations made may create conflicts with other 
priorities in the individual's life which may best be dealt with by changing the recommendations 
made without necessarily compromising the level of diabetes control that can be achieved. 
 
Thus, in the complex field of diabetes management, the notion of self-care behavior is far more 
useful than the concept of 'adherence'. It can be useful and constructive to investigate self-care 
behavior and to explore the reasons for actions taken and consider the extent to which the actions 
were likely to result in the intended outcomes (and avoid unwanted outcomes) given the 
circumstances concerned. While it is neither necessary nor helpful to ask whether the actions 
were 'adherent' it can be useful to assess self-care activities and efforts have been made to do so 
(Toobert & Glasgow, 1994). 
 
A useful review of the complexities in attempting to apply the concept of 'compliance' to diabetes 
management is provided by Glasgow (1991).  
 
 
4.7. PSYCHOLOGICAL INTERVENTIONS IN THE MANAGEMENT OF DIABETES 
 
4.7.1. Blood Glucose Awareness Training (BGAT) and Other Approaches to Regaining 
Hypoglycemia Awareness  
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Cox, Gonder-Frederick and their colleagues at the University of Virginia developed a program of 
Blood Glucose Awareness Training (BGAT) to train individuals with diabetes to recognize their 
level of blood glucose. The BGAT program and associated manual (Cox et al. 1992) is based on 
blood glucose monitoring together with monitoring of physical symptoms, mood and 
environmental cues associated with each blood glucose reading in order to identify the symptoms 
and cues which predict high blood glucose levels and those which predict low blood glucose 
levels for each individual. Cox and his colleagues developed an error grid analysis to identify 
those errors made in estimating blood glucose which matter clinically. Efforts are then focused 
on reducing the errors that would be clinically important such as failing to detect extreme blood 
glucose levels, or mistaking an acceptable blood glucose level for one that is too high or too low. 
 
BGAT has been shown to be effective in teaching individuals with IDDM to improve their 
accuracy in recognizing blood glucose levels. Associated improvements in diabetes control have 
also been found with improved glycosylated hemoglobin results in BGAT patients compared 
with untrained control patients (Cox et al. 1991). Long-term follow-up has shown that 
participants in the BGAT training program had had fewer episodes of severe hypoglycemia and 
fewer car crashes than controls at five-year follow-up (Cox, Gonder-Frederick, Julian & Clarke, 
1994). More recently, BGAT-2 has been developed to increase sensitivity to low blood glucose 
levels, and benefits have included fewer motoring offenses and car accidents, and fewer 
nocturnal episodes of severe hypoglycemia (Cox, Gonder-Frederick Kovatchev, et al. 1995). A 
multi-center trial of BGAT-2 used by clinicians other than those in the original research team 
developing the program, suggested that BGAT-2 offers a useful strategy for treating the 
disabling problem of hypoglycemia unawareness. BGAT-2 improved detection of low blood 
glucose levels in individuals who had reported impaired hypoglycemia awareness on recruitment 
to the study (Cox, Gonder-Frederick, Polonsky, et al.1995). There is increasing evidence that 
patients who have lost their warning symptoms of hypoglycemia can learn to attend to new signs 
of hypoglycemia which may be physical, cognitive or mood symptoms or may be circumstantial 
indicators that hypoglycemia is likely (e.g. running for a bus when late for a meal).  
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Another approach to treating loss of awareness of hypoglycemia has been to avoid hypoglycemia 
by diet review, advice about exercise and redistribution of insulin in patients with hypoglycemic 
unawareness (Cranston et al. 1994; Fanelli et al. 1993). After at least three clear weeks without 
hypoglycemia, patients became aware of symptoms of hypoglycemia. Adrenaline responses were 
more marked at higher blood glucose levels than was previously the case, and at levels higher 
than those at which cognitive impairment was indicated by a reaction-time task (Cranston et al.) 
It has been suggested (Bradley & Gamsu, 1995) that in attempting to avoid hypoglycemia, 
participants in such studies may learn to become more sensitive to neuroglycopenic symptoms at 
higher levels of blood glucose than they were before. Thus, the intervention to avoid 
hypoglycemia, may act as an indirect form of BGAT. It is also possible that the success of 
BGAT in increasing awareness of hypoglycemic symptoms may in part be due to a reduction in 
occurrence of hypoglycemia. 
 
 
4.7.2. Identification of Stress Reactivity 
 
 4.7.2.1.Mechanisms involved in stress and diabetes control 
 
Stress may affect metabolic control in diabetes in at least two ways (Barglow, Hatcher, Edidin & 
Sloan-Rossiter, 1984): 
(i)  a direct psychophysiological effect via sympathetic and pituitary activity which results in the 
elevation of catabolic hormone levels and the suppression of anabolic hormones. In people with 
diabetes, this may result in increased blood glucose levels, although, for a small minority, less 
readily understood decreases in blood glucose levels result. 
  
(ii)  a behavioral mechanism whereby stress leads to behavioral changes capable of disrupting 
self-care behavior. (Barglow et al. 1994). For example, time urgency may make blood glucose 
monitoring and well-balanced meals impractical leading to disruptions in metabolic control. 
Glycemic fluctuations themselves can contribute to the behavioral changes via impaired 
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cognitive function (Holmes, Hayford, Gonzalez & Weydert, 1983; Ryan, 1994; Wang et al. 
1993), which, for example, may cause poor self-care responses to feedback from blood glucose 
monitoring.  A two way causal link between stress and diabetes control has been suggested 
(Bradley, 1988)  whereby life events cause disruption in diabetes control which in turn causes 
increases in the number of life events.  
 
 
4.7.2.2. Acute stress and blood glucose reactivity 
 
Several seemingly well-controlled acute stress studies conducted in the 1980's 
reported no significant changes in blood glucose control in response to potential 
stressors such as mental arithmetic and public speaking  (Edwards & Yates, 1984;  
Kemmer et al.1986; Naliboff, Cohen & Sowers, 1985). However, this work 
overlooked the possibility that the commonly observed individual differences in 
response to stress might be real and interesting, and not a reflection of methodological 
inadequacies (Bradley, 1988). More recent studies of experimental stress have 
examined physiological mechanisms hypothesized to mediate the relationship 
between psychological stress and blood glucose control.  There is evidence that 
reduced blood flow to the insulin injection site (Hildebrandt, Mehlsen, Sestoft & 
Nielson, 1985) and insulin resistance over several hours (Moberg,  Kollind, Lins & 
Adamson, 1994) may cause increased blood glucose levels in individuals with IDDM 
in response to acute laboratory stressors. It has been noted elsewhere (Bradley & 
Gamsu, 1995) that laboratory studies with a short time frame are likely to 
underestimate such long-lasting effects of stress on blood glucose. 
 
The effects of a laboratory stressor (Stroop test) on changes in blood flow at the insulin injection 
site have been studied in IDDM patients (Greenhalgh,  Jones,  Jackson,  Smith  & Yudkin, 1991). 
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The results showed that mean levels of blood glucose rose in some patients and fell in others in 
response to acute stress, and that these changes were largely explicable in terms of changes in 
free insulin levels, which in turn were partially mediated by changes in injection-site blood flow. 
The authors proposed that vasodilation at the subcutaneous insulin injection site may in some 
cases lead to a paradoxical hypoglycemic effect during acute stress via an increased rate of 
absorption of insulin, an effect which will be counterbalanced to a greater or lesser degree by 
increases in counter-regulatory hormones. In other individuals, absorption of insulin may fall 
during stress and contribute to hyperglycemia. Again these findings underline the importance of 
looking at individual differences. 
  
Idiosyncratic blood glucose responses which were reliable across a 12-week time period within 
individuals with  IDDM have been reported in response to caffeine and to the competitive 
playing of a video game (Carter, Gonder-Frederick, Cox, Clarke & Scott, 1985). A more recent 
study from this research group (Gonder-Frederick, Carter, Cox & Clarke, 1990) has reported 
similar results. Such studies suggest that the inconsistent findings of previous research may have 
resulted because of differences in the stress-responsiveness of the individual patients recruited. 
 
4.7.2.3. Life stress and blood glucose reactivity 
Studies of major life events and diabetes control have suggested that increased life events are 
associated with raised blood glucose levels (Chase & Jackson; 1981; Barglow et al. 1994).  
However, within-subject variations in stress and in blood glucose values would have been 
obscured by the methods used which correlated aggregated retrospective reports of life events 
with GHb or HbA1 measures of averaged blood glucose, thereby oversimplifying the picture. 
Recent research has begun to look at the relationship between minor daily events and diabetes 
control (using serial blood glucose measurements) in order to overcome the methodological 
limitations of the earlier studies of life events - blood glucose relationships. 
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Investigations of daily stressful events are providing more interpretable results with studies 
reflecting individual differences in response to stress that were also seen in some of the 
laboratory based acute stress studies. Although the overall picture suggests that increased daily 
stress correlates with increased blood glucose levels in IDDM (Hanson & Pichert, 1986) and in 
NIDDM (Goetsch, Abel & Pope, 1994), examination of individual's  blood glucose response to 
stress indicates that some people display stress-reactivity and some people do not. Halford,  
Cuddihy and Mortimer (1990) found that approximately half the sample of 15 IDDM participants 
had significant associations between stress and blood glucose levels, and that this association 
was independent of the effects of diet and exercise self-management.  
 
Within those people who do display stress-reactivity, most show an increase in blood glucose 
while a few show a decrease in blood glucose (Aikens, Wallander, Bell & McNorton, 1994; 
Riazi, Pickup & Bradley, 1996).  Aikens and colleagues studied twenty-five women with IDDM 
who monitored daily stress and blood glucose for 30 consecutive days. Blood glucose was found 
to be higher on high-stress days than on low-stress days, with 8 of the 25 subjects showing 
significant positive associations between stress and same-day blood glucose. Stress showed little 
relation to next-day blood glucose, although two subjects showed associations (one positive and 
one negative). In a recently conducted study of 54 men and women with IDDM which measured 
daily stress and blood glucose levels over a three week period (Riazi et al. 1996), individual 
differences were marked in the magnitude, direction and duration of blood glucose stress 
reactivity. Those with higher levels of HbA1 indicating poorer control of diabetes, were more 
stress-reactive than those with lower levels of HbA1. 
 
These findings show the individual differences in response to stress that can be seen in laboratory 
based acute stress studies which investigate individual differences but are not seen in studies 
which limited the analysis to group differences or in studies of life events using average 
measures of blood glucose. Although increases in blood glucose levels are the most common 
form of stress reactivity, decreases are not uncommon and there is a need for individuals to 
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discover empirically how their own blood glucose levels respond to different kinds of stress in 
order to take appropriate action to prevent or correct disruptions in diabetes control. 
 
 
4.7.3. Stress Management Training  
 
The overly simple model of life stress causing raised blood glucose levels has inspired the use of 
stress management training, particularly relaxation training, as an aid to diabetes control. 
Relaxation is thought to decrease adrenocortical activity (Jevning, Wilson & Davidson, 1978; 
DeGood & Redgate, 1982) as well as circulating levels of catecholamines (Mathew, Ho, Kralik, 
Taylor & Claghorn, 1980; Mathew, Ho, Kralik, Taylor, Semchuk, et al. 1980) and hence is 
expected to prevent stress-induced increases in blood glucose levels.  
 
The research to date supports the view that stress management techniques may be valuable to aid 
diabetes management for some people but not with others. It has been suggested (Bradley, 
1994a)  that relaxation techniques are unlikely to do harm except when blood glucose is already 
tightly controlled (Seeburg & DeBoer, 1980) and the insulin dosage is not appropriately reduced 
to balance the effects of relaxation on insulin requirements (which may well be reduced) and/or 
when used at a time when blood glucose is already low (<4 mmol/L) and there is a risk of 
hypoglycemia. It is important to take the precaution of measuring blood glucose immediately 
before all relaxation training or practice sessions. Twenty minutes of relaxation can lead to a 
drop in blood glucose as great as 3 mmol/L. Such a substantial fall is only likely if blood glucose 
is well above the normal range of 4-6 mmol/L to start with and probably results from a 
suppression of catecholamine secretion. It is recommended that relaxation training should not be 
conducted at blood glucose levels below 4 mmol/L because of the risk of hypoglycemia. 
Relaxation training might be continued if the anticipated reduction in blood glucose were 
counteracted with pre-training intake of slow release carbohydrate (e.g. an apple). A further 
precaution of measuring the blood glucose after a relaxation session, before leaving the 
therapist's office, is also recommended to avoid the risk of hypoglycemia while traveling home. 
 
 
 
 
31 
 
Several studies have reported some success with improvements in diabetes control following 
relaxation training (usually involving EMG biofeedback) in NIDDM and IDDM patients 
(McGrady, Bailey & Good, 1991; McGrady & Gerstenmaier, 1990; Rosenbaum, 1983; Surwit & 
Feinglos, 1983). There is evidence to suggest that  relaxation training is least useful for those 
subjects whose glycemic control was good to start with and most useful when used by subjects 
who not only had poor control of their diabetes but who felt that stress disrupted their diabetes 
control and who were currently experiencing stressful events (Bradley, Moses, Gamsu, Knight & 
Ward, 1985; Lammers, Naliboff & Straatmeyer, 1984).  
 
In contrast, Feinglos, Hastedt and Surwit (1987) found no significant effect of relaxation training 
in people with poorly controlled IDDM who reported stress-induced hyperglycemia. After 6 
weeks in which the trial group practiced relaxation techniques at home, measures of glucose 
tolerance, GHb levels (which reflect blood glucose levels over 6-8 weeks), and insulin 
requirements did not differ between relaxation and control groups. Unfortunately, the authors did 
not provide any information about the variability of the individual patients.  
 
In a more recent study, Lane, McCaskill, Ross, Feinglos & Surwit (1993) investigated 38 people 
with NIDDM who were treated with intensive conventional diabetes therapy (including diabetes 
education and dietary interventions) with half of the subjects assigned at random to receive 
biofeedback-assisted relaxation training. Both groups demonstrated significant improvements in 
GHb level after 8 weeks, but not in glucose tolerance. No added benefit of relaxation training 
was seen on either measure though it was found that those subjects who showed improvements in 
glucose tolerance after pretreatment with the anxiolytic drug alprazolam also showed 
improvements in glucose tolerance after relaxation training. It was also found that subjects who 
responded best to relaxation training were those scoring higher on measures of trait anxiety. 
Overall, the authors concluded that relaxation may be useful for the treatment of neurotic, 
anxious, and autonomically reactive individuals but may be ineffective for other patients. Lack of 
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selection of patients likely to benefit from relaxation training may have been responsible for the 
nonsignificant finding of relaxation of the group as a whole. 
 
What is emerging from the studies of relaxation training on people with diabetes, is that it is 
most useful for those who show stress-related disturbance of blood glucose control or for those 
who are anxious and autonomically reactive. The degree to which these groups overlap is as yet 
unclear though there is some evidence to suggest that the groups may be separate. Self-reported 
anxiety did not correlate with blood-glucose reactivity to stress in the studies of Riazi et al 
(1996). Assessment of subjects' stress-reactivity before embarking on relaxation training in 
future studies will help in the identification of patients most likely to benefit from relaxation 
training. To date, most studies have incorporated biofeedback into the relaxation training. 
Relaxation training on its own would be more practical and less costly. There is limited evidence 
that biofeedback is an unnecessary addition for most people (Bradley et al. 1985). Evaluation of 
low-technology forms of relaxation training with patients shown to be stress reactive would be a 
useful next step. 
 
 
4.7.4. Monitoring of Psychological Outcomes and Processes 
 
Just as measurement of blood glucose is essential to the task of achieving and maintaining tight 
control of diabetes, the measurement of psychological outcomes is central to protecting and 
improving the quality of life of people with diabetes. However, while measurement of blood 
glucose is standard practice in diabetes management and research, measurement of psychological 
outcomes is, as yet, common only in research settings. Quality of life measurements are now 
increasingly recognized as essential parameters in clinical trials evaluating new treatments for 
diabetes and improvements in aspects of quality of life are often among the primary outcomes to 
be investigated. Treatments including insulins and insulin delivery systems are being developed 
to be more convenient and flexible and compatible with quality of life. There is growing 
recognition that the desired biomedical outcomes are more likely to follow if treatment regimens 
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are convenient and flexible and can be integrated into individual's lives without impairing the 
quality of life. Although measurement of psychological outcomes in routine clinical practice is 
far from standard practice, recent initiatives are encouraging such developments. The St. Vincent 
Declaration Action Programme for diabetes care in Europe has recommended the routine 
measurement of psychological well-being and patients' satisfaction with treatment in the 
monitoring of diabetes management (Bradley & Gamsu, 1994; Krans et al. 1995), and many 
national initiatives are now underway including a national study of monitoring of diabetes care in 
the UK (Wilson et al.1993), and an initiative in the Netherlands to evaluate the effects of routine 
monitoring of the psychological outcomes recommended by the St. Vincent Guidelines F.J. 
Snoek and colleagues, personal communication, 1996).  
 
4.7.4.1. Measurement of psychological well-being and patient satisfaction 
 
The measures recommended in the St. Vincent Guidelines are the Well-being Questionnaire 
(Bradley, 1994b, Bradley & Lewis, 1990) and the Diabetes Treatment Satisfaction Questionnaire 
(Bradley, 1994c) which were designed and developed specifically for people with diabetes. The 
Well-being Questionnaire was first designed in the early 1980's for diabetes clinical trials 
because it was recognized that generic instruments to measure depression or anxiety are 
unsuitable for people with diabetes. Measures such as the Beck Depression Inventory (Beck, 
Ward, Mendelson, Mock & Erbaugh, 1961), developed for the general population,  include items 
concerned with somatic symptoms which may well be indicative of depression in the population 
as a whole but in a diabetic sample are more likely to result from inadequate blood glucose 
control. For example, symptoms of fatigue, appetite disturbances, weight loss, sleep 
disturbances, irritability and loss of sexual interest can all be symptoms of high blood glucose 
levels. At around the same time and for the same reasons, Zigmond and Snaith (1983) developed 
the Hospital Anxiety and Depression (HAD) scale to focus on cognitive symptoms and avoid 
somatic symptoms. The HAD was intended to be appropriate for use with hospital patients and 
encouragingly, recent work with diabetic populations has confirmed the original factor structure 
of the HAD (McColl et al. 1995).  
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The Well-being Questionnaire has subscales to measure depression and anxiety which are similar 
to those of the HAD but, unlike the HAD, also has subscales to measure energy and positive 
well-being. These additional subscales are more sensitive to change than the depression and 
anxiety (Bradley, 1994b) and the Well-being Questionnaire is likely to be more sensitive than the 
HAD to positive benefits of new treatments for diabetes. If only depression and anxiety scales 
are used, the optimal state measurable is an absence of depression or anxiety and floor effects 
occur if, as usually happens, in diabetes research, patients are not depressed or anxious when 
baseline measures are taken. The World Health Organization (WHO) has recommended wider 
use of the Well-being Questionnaire with other patient groups in addition to those with diabetes, 
in a context of continuing development (WHO Regional Office for Europe Consensus Meeting 
on Quality Assurance Indicators, Stockholm, August 1993 and November 1995). As with the 
HAD scale, care is needed when using the instrument with a different population of patients as, 
despite efforts to reduce confounding of depression scores with symptoms of poorly controlled 
diabetes,  different illnesses may influence responses in different ways. Efforts to improve and 
evaluate translations of the Well-being Questionnaire in European and other languages have been 
associated with the widespread use of the instrument in multi-national clinical trials and in the St. 
Vincent European monitoring initiative and work is underway to meet the demand for a 
shortened version of the 22-item Well-being Questionnaire which will facilitate use of the 
instrument in routine clinical practice (Bradley,1996a).  
 
The Diabetes Treatment Satisfaction Questionnaire (DTSQ) (Bradley, 1994c; Bradley & Gamsu, 
1994; Krans et al. 1995), is a single-page instrument that has been widely used in clinical trials 
and is valued for its sensitivity to change in response to alterations to diabetes treatment 
regimens. A broader, though less detailed, single-page measure of satisfaction with the diabetes 
clinic service (The Diabetes Clinic Satisfaction Questionnaire, DCSQ) has since been developed 
to meet the need to audit patients' satisfaction with the service as a whole as well as, more 
specifically, with their particular treatment regimen (Wilson et al. 1993). The DCSQ is designed 
to identify sources of dissatisfaction so that efforts to improve the service can be well informed. 
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This instrument is being used in the UK national study of audit of diabetes care steered by the 
Diabetes Information Managment and Audit Committee of the British Diabetic Association. 
(Wilson et al.). 
 
The use of diabetes-specific instruments such as the Well-being Questionnaire, DTSQ and 
DCSQ allows for instruments which focus on issues of particular relevance to the diabetic 
population. The instruments can be short because issues of little concern in diabetes can be 
excluded. Although generic instruments are less likely than diabetes-specific instruments to be 
sensitive to changes following changes in treatment for diabetes, there is some demand for 
generic instruments which comes particularly from health service managers and health 
economists who want to compare outcomes in different patient groups. The reader is referred 
elsewhere for a review which considers the use of generic measures with diabetic populations 
(Bradley, 1996b).  
 
4.7.4.2. Measurement of quality of life  
 
The phrase 'quality of life measures' is often indiscriminately used to cover health status 
measures, well-being and satisfaction measures and even measures of self-reported symptoms as 
well as measures of how good or bad life is felt to be. Focusing here on the latter group of 
measures, an important distinction can be made between individualized measures and those 
which are not tailored to the individual. 
 
With most measures of quality of life, diabetes-specific or generic, the aspects of life deemed to 
be relevant to quality of life are specified by the designers of the questionnaire. Although the 
choice of aspects of life may have been informed by prior research with samples of people with 
diabetes and by input from health professionals involved in diabetes care, there is no scope for 
the individual respondent to decide if any one particular aspect of life asked about is applicable 
to them and, if it is, whether it is important to their quality of life. The Diabetes Quality of Life 
(DQOL) measure used in the Diabetes Control and Complications Trial includes 56 items which 
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all receive equal weight regardless of their relative importance to the individual (Jacobson et al. 
1994).  It has been suggested that the lack of differences reported between DQOL scores of those 
who intensified their treatment in the trial and those who did not may be attributable to the 
limitations of the measure rather than to any real lack of impact of intensification of treatment on 
quality of life (Bradley, 1994d). Thus an item concerned with immediate and pervasive worries 
about hypoglycemia which may markedly impair an individual’s quality of life will have no 
more impact on the DQoL total score than an item concerned with  satisfaction with time taken 
to determine blood glucose levels or an item about how often the individual has to explain what 
it means to have diabetes.  The DCCT research group reported that the DQoL total scores 
showed no impact of intensified treatment on quality of life (DCCT, 1993). This was surprising 
given the considerable increase in severe hypoglycemia experienced by the intensified treatment 
group in the DCCT, but not surprising when the nature of the quality of life measure used is 
examined. 
 
Individualized measures of quality of life ask the individual respondent which domains are 
important to his or her quality of life. An increasingly valued measure of individual quality of 
life is the Schedule for Evaluation of Individual Quality of Life (SEIQoL) interview method 
(Hickey et al.1996; McGee, O'Boyle, Hickey, O'Malley & Joyce, 1992; O'Boyle, McGee, 
Hickey, O'Malley & Joyce, 1991). The SEIQoL establishes in interview the domains of life 
important to a particular individuals quality of life, elicits ratings for each domain from 'as good 
as it could possibly be' to 'as bad as it could possibly be', determines weights for each domain 
using a method of judgment analysis. The philosophy underpinning the SEIQoL has influenced 
the design of a questionnaire measure for Audit of Diabetes Dependent Quality of Life 
(ADDQoL) (Bradley, Todd, Gorton, Plowright & Symonds, 1995; Todd, Bradley & Symonds, 
1993). The ADDQoL includes a series of domains identified in pilot work to be commonly 
affected by diabetes and its treatment. Working life and family life are two of the standard 
domains included together with worries about the future, enjoyment of food and other items 
more specifically relevant to diabetes. Each domain is first rated for the impact of diabetes on 
that domain and then rated for the importance of that domain for quality of life. Domain ratings 
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are then multiplied by importance ratings such that a domain which is unimportant will score 
zero regardless of how much it is affected by diabetes while ratings other than zero for an 
important domain will receive greater weight. Any domain that is said to be inapplicable is 
ignored. The weighted ratings of all applicable domains are then summed and divided by the 
number of applicable domains to give scores which vary from the same maximum (+9) to the 
same minimum (-9) for all individuals. In this way, the ADDQoL, like the SEIQoL, focuses on 
applicable domains that are important to the particular individual. Unlike the SEIQoL, the 
ADDQoL is specifically concerned with the effects of diabetes and its treatment on quality of 
life. The ADDQoL provides a framework which is readily modified to be suitable for use with 
other patient groups and is currently being adapted for use with renal patients. There is now 
considerable interest in patient-centered measures of quality of life and although other measures 
aim to be relevant by ensuring that item design is informed by qualitative work with patients, few 
instruments are patient-centered in providing opportunities for patients to indicate which items 
are relevant to them personally and which are not and to provide their own weightings of 
importance for each relevant item (Greenhalgh, 1996; Bradley, 1996b). 
 
4.7.4.3. Measurement of knowledge, beliefs and other cognitions. 
Many different measures of knowledge of diabetes were designed and developed in the 1980's 
but more recently there has been widespread disenchantment with such measures (Glasgow, 
Toobert, Hampson & Wilson, 1995). This has resulted in part from the abstract content of some 
knowledge measures and partly from the inappropriate expectation that knowledge of diabetes 
will correlate with measures of blood glucose control (Beeney, Dunn & Welch, 1994). When no 
correlation is found the validity of the knowledge questionnaire has been questioned. However, 
there is no logical reason to expect that responses to many of the items on knowledge 
questionnaires will correlate with blood glucose levels (e.g. items concerned with foot care). In 
addition, validation of knowledge items is complicated by the fact that patients often acquire 
considerable knowledge after they develop a problem, thereby leading to counterintuitive 
associations between knowledge and outcomes in cross-sectional surveys. Care and ingenuity is 
needed to select appropriate methodologies to develop knowledge measures for particular 
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purposes (Bradley, 1995). In the light of continuing evidence of inadequate levels of knowledge, 
with patients with NIDDM being particularly disadvantaged (Anderson, Hiss, Stepien, Fitzgerald 
& Funnel, 1994), the measurement of knowledge and provision of remedial education as required 
is likely to result in marked improvements in biomedical and psychosocial outcomes of diabetes 
care.   
 
Other measures of psychological processes which can be valuable in understanding difficulties 
with diabetes management include measures of health beliefs, and perceptions of control, or 
locus of control, of diabetes. A variety of reliable diabetes-specific measures  have been 
validated for various purposes (Bradley, 1994e; Kohlmann et al. 1993; Lewis & Bradley, 1994). 
Measures of health beliefs and, particularly measures of  patients’ attributions or locus of control, 
have proved useful in understanding patients preferences for injection treatments or continuous 
subcutaneous insulin infusion (CSII) pumps, and in understanding why some patients developed 
the dangerous acute complication, diabetic ketoacidosis (DKA), during pump use (Bradley, 
Gamsu, Knight, Boulton & Ward, 1986; Bradley et al.1987).  
 
In a feasibility study involving all insulin treated patients at the Royal Hallamshire Hospital in 
Sheffield (Knight et al. 1984), patients were offered the choice of CSII pumps, intensified 
injection treatment or conventional injection treatment.  An illustrated lecture informed patients 
about the treatments available and patients were told that “the evidence suggests that CSII 
controls blood glucose levels better than injections”.  Unfortunately, only with hindsight was it 
realized that patients needed to know, but had not been told, that the effectiveness of CSII 
depended on the actions of the individual user and that CSII required at least as much, if not 
more, thought, effort and precautions to use it effectively and safely, than was needed with   
injection therapies.  Those attracted to CSII tended to be those who were seeking a medical 
solution for their condition and who had less sense of personal control over their diabetes (as 
measured by the perceived control of diabetes scales). Sadly, it was those with the strongest 
sense of medical control and least sense of personal control who did least well with CSII pumps 
both in terms of blood glucose control at 12 months (Bradley et al. 1987), and occurrence of 
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DKA during the study (Bradley et al. 1986). A massive increase in rates of diabetic ketoacidosis 
occurred among CSII users in the first two years of the study, and the only variables to 
discriminate between those who developed DKA and a matched group of those with no DKA 
were the psychological variables, perceived control and health beliefs. 
 
Although questionnaire measures of health beliefs and cognitions  are somewhat cumbersome for 
clinical use, experience with the tools in a research context and in detailed assessment of 
individuals presenting with particular problems can be valuable. The concepts underlying the 
measures can usefully guide clinical interviews seeking to establish sources of difficulty with 
diabetes management with a view to tailoring the treatment to suit the individual patient and 
identifying inappropriate beliefs and expectations of treatments which need to be addressed. 
 
The Handbook of Psychology and Diabetes (Bradley, 1994f) provides ready access to most of 
the questionnaire measures described above and provides reference to yet more measures. 
Despite the availability of such measures and increasing evidence for their value in clinical as 
well as research contexts, there is resistance among some clinicians to monitoring psychological 
outcomes (Barendse, 1995). The unfamiliarity of the tools leads many physicians to feel that they 
would need training in use of the instruments before they would feel able to use them. There is 
also concern about how they would deal with cases of depression and anxiety which may be 
brought to light as a result of using the questionnaires. These are both understandable concerns 
which may be dealt with by involvement of psychologists to support use and interpretation of the 
psychological measures and in helping to deal with psychological problems identified. 
Interestingly one source of resistance to using the instruments was the reported concern that 
patients would not want to have psychological outcomes considered as part of routine diabetes 
care though all the available evidence suggests that quite the reverse is the case: people with 
diabetes and parents of children with diabetes have long complained about the excessive 
emphasis on their blood glucose levels in diabetes clinics while little attention is paid to the 
effects of diabetes management on their lifestyle and quality of life. Clinical psychologists have 
an important role to play in encouraging and supporting diabetes care teams in measuring 
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psychological outcomes and in taking action to protect or improve the psychological outcomes of 
people with diabetes. 
 
4.7.5. Patient Empowerment   
 
With diabetes, as much if not more than with other chronic illnesses, optimal  management  can 
only be achieved by means of complex behavioral changes on the part of the patient. It is not 
enough for the clinician merely to give instructions. Health professionals are increasingly 
working towards holistic approaches to treatment, which include an emphasis on providing the 
education, support and encouragement to enable patients, where possible, to manage their own 
diabetes. Indeed, the 2nd edition of the St. Vincent Declaration Action Programme to improve 
diabetes care in Europe (Krans et al. 1995) now includes specific guidelines to facilitate patient 
empowerment. 
 
The construct of empowerment has been in use in other domains of psychology for some time,  
and has at times been both ill-defined and misunderstood. In the context of diabetes care, a useful 
overview of patient empowerment has been provided by Anderson (1995).  
 
The 'empowerment' of individual patients is a complex goal.  It requires first that  patients have a 
level of authority and responsibility to be able to make decisions and manage their own 
treatment.  Secondly,  it requires that they  be willing to accept that responsibility and to achieve 
the necessary skills and knowledge to make them capable of managing their diabetes.  And 
thirdly, the environment of care needs to be such that policies and practices facilitate self-
management of diabetes care.  Central to the achievement of each of these elements is the health 
care professional.  He or she must accept patients as active and responsible self-carers, educate 
them both in knowledge of diabetes and self-care choices, and facilitate the setting of individual 
goals of self care through an assessment of individual preferences.  Patently, this becomes even 
more vital in an age of technologically advanced  health-care systems, where the tendency may 
be to alienate patients from active participation in their own medical treatment (Stabler, 1993).  
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Whilst numerous accounts of  research  into patient empowerment  may be found,  the literature  
specific to diabetes care is as yet limited, but growing (Anderson, 1995; Anderson,  Funnell, 
Barr, Dedrick & Davis, 1991;  Anderson, Funnell, Butler, Arnold & Feste, 1995; Doherty et al, 
1996; Feste, 1992;  Kinmonth et al. 1996). In looking to the future for a more widespread 
adoption of attitudes and practices which facilitate patient empowerment, it is clear that certain 
barriers need to be overcome.  Some patients may be reluctant to accept responsibility for their 
own diabetes management, and need to be encouraged with the knowledge that they are best 
placed to make decisions which impact on the day to day running of their lives. They then need 
access to professional support, education in the knowledge of their condition, self-care skills and 
choices available to them.  Health care professionals may also misunderstand patient 
empowerment.  They may see this as an unethical suggestion that they should abdicate 
responsibility for care and relinquish clinical control and decision making.  At the other end of 
the spectrum, some may see patient empowerment as a license to divest themselves of the more 
intractable problems associated with diabetes care.  In reality, however, patient empowerment 
involves active participation of the health professional in the role of facilitator,  enabling patients 
to set individual goals for diabetes management and to achieve optimal outcomes in both medical 
and psychosocial health.   
 
There is early evidence for the success of patient empowerment interventions.  Anderson et al. 
(1995) reported a randomized waiting-list control group trial of patient empowerment education. 
Despite some problems associated with drop-out rates and the combination of data from 
randomized and non-randomized participants for analysis, the results suggested a modest 
improvement in blood glucose control, along with gains in self-efficacy and attitudes toward 
diabetes. 
 
Greenhalgh, Chowdhury & Helman (1996) evaluated a patient empowerment model with  a 
sample of British Bangladeshis with diabetes, and identified a variety of culturally-related factors 
which   may create obstacles to patient empowerment including ignorance about diabetes and 
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available services, poverty, fatalism, and religious convictions. These findings underline the need 
for individual patient focus in empowerment programs if those programs are to be appropriate to 
patients needs. Quatromoni,  Milbauer, Posner, Carballeira, Brunt &  Chipkin (1994) described a 
study which used focus groups to explore culture-specific information that could be useful in 
empowerment interventions with Caribbean Latinos with NIDDM.  Amongst the issues they 
identified were “feelings of social isolation, little understanding of long-term consequences of 
diabetes, fatalism regarding the course of the disease, barriers to diet and exercise interventions, 
skepticism regarding the value of preventive health behaviors, and a clear need for culturally-
sensitive health-care provision” (Quatromoni et al. 1994, p869). Similarly, the Haida Gwaii 
Diabetes Project (Herbert, 1996) described an approach which uses community-based research to 
identify a culturally-sensitive approach to diabetes prevention and management.  Outcomes 
suggest an empowerment benefit to individuals with diabetes, their families, and community.  
Moreover, there were reported benefits to health care professionals, in that they also felt 
empowered to implement diabetes care in ways which were more pertinent to patients. 
 
Early evidence suggests that patient empowerment offers a promising way forward in diabetes 
care. It is perhaps worthwhile, however, to sound a cautionary note. Should empowerment 
interventions fail to show significant benefits in the future,  it may be that the interventions 
themselves have not been adequate to the task, either in that health professionals did not receive 
adequate training to enable them to move to more participative care,  or that the empowerment 
goals were not sufficiently focused on the cultural or individual needs of patients. 
 
 
4.7.6. Weight Management  
 
Weight management is a problem both for people with IDDM, and NIDDM in rather different 
ways. People with IDDM need to balance their carbohydrate intake, insulin and exercise in order 
to control their blood glucose levels. Current dietary recommendations tend to be less restrictive 
than was the case in the 1980s though typically patients would be advised to avoid foods 
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containing simple sugars (sweets, cakes, sugary drinks etc.) and foods with a high fat content. 
Paradoxically if they develop hypoglycemic symptoms they need to take instantly available 
glucose to avoid a severe hypoglycemic episode which can lead to coma. The consequent rise in 
blood glucose may overshoot and result in hyperglycemia. If their carbohydrate intake is too 
high, an increase in insulin dose will be needed to maintain metabolic control and, as with people 
who do not have diabetes, carbohydrate excess will lead to weight gain. However, in people with 
diabetes, crash diets to deal with unwanted weight may result in metabolic chaos and a careful 
weight reduction program is needed which balances reduced carbohydrate intake and/or 
increased exercise with reduced insulin doses.  
 
4.7.6.1. Eating disorders and withholding of insulin 
Adolescent girls with IDDM tend to be heavier than matched non-diabetic girls for reasons 
which are not understood, and are likely to be dieting more intensely in order to control their 
weight. In cross-sectional and case-controlled studies (Fairburn, Peveler, Davies, Mann & 
Mayou, 1991; Peveler, Fairburn, Boller  & Dunger, 1992), eating disorders have been found to 
be as prevalent but not more common in young women with IDDM than those without. Nine per 
cent of adolescent girls in the latter study met the diagnostic criteria for 'eating disorder not 
otherwise specified' in the ICD (International Classification of Diseases) classification. Other 
studies have indicated that adolescents and young women with diabetes are at greater risk of 
eating disorders than those who do not have diabetes (Rodin, Daneman, Johnson, Kenshole & 
Garfinkel, 1985;  Rosmark et al.1986). However, care needs to be taken over the methods used to 
identify eating disorders in people with diabetes. Generic eating disorder self-report assessments, 
such as the Eating Attitudes Test (EAT) or Eating Disorder Inventory (EDI) are likely to yield 
different scores from people with diabetes because of the emphasis on diet and dietary restraint 
in diabetes education. Items such as I “avoid foods with sugar in them” and “engage in dieting 
behavior” on the EAT and “I eat sweets and carbohydrates without feeling nervous” on the EDI 
may be useful indicators of eating disorders in the general population, but in people with 
diabetes, responses will be affected by the diabetes treatment regimens commonly recommended. 
Efforts have been made to control for this bias by excluding from the EAT and EDI those items 
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which would be answered significantly differently by those with diabetes (Cantwell & Steel, 
1996;  Steel, Young, Lloyd & Macintyre, 1989). However, further evaluation is needed before 
these modified measures can be used with confidence in studies involving people with diabetes.  
Rodin and Daneman (1992), in a review of this literature suggested that the reliability of 
prevalence rates for 'caseness' is improved when based on structured interviews and standardized 
diagnostic criteria such as ICD-9, rather than self-report questionnaires which are often used in 
prevalence studies.   
 
However disordered eating has been found to be common even in more methodologically 
rigorous studies I addition to more commonly recognized eating disorders and Peveler and 
colleagues (1992) also reported that 15% of their sample were omitting or reducing their insulin 
in order to reduce their weight. Insulin withholding has also been found to be associated with 
current or past symptoms of anorexia or bulimia nervosa (Biggs, Basco, Patterson & Raskin, 
1994). When insulin is withheld, blood glucose levels will rise until they reach the renal 
threshold (10mmol/L) and then glucose will be excreted in the urine taking with it water which 
would otherwise have been retained. Thus, withholding of insulin is a means of effortless weight 
loss though not without potentially serious consequences. In particular, the chronic 
hyperglycemia of a person who habitually withholds insulin to lose weight, will put the 
individual at risk of diabetic ketoacidosis requiring hospitalization in the short term (if they omit 
insulin for too long a period)  and, in the longer term, the risk of microvascular complications of 
diabetes is markedly increased. Pediatricians responsible for the care of adolescents with diabetes 
may well downplay concerns about future complications for fear of alarming young patients and 
their parents and it can therefore be quite possible for young people with diabetes to be ignorant 
of the now well-established causal link between chronic hyperglycemia and the serious 
microvascular complications which are the reasons for concern that motivate the clinicians to 
attempt to improve diabetes control. Where young people with IDDM are well informed about 
the risks of microvascular complications and the importance of blood glucose control for 
reducing those risks, the attractions of quick and easy weight loss may nevertheless outweigh the 
more distant concerns of complications in 15 years or so and by injecting some insulin 
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occasionally, the dangers of diabetic ketoacidosis and associated coma may be avoided. 
Withholding of insulin thus presents a diabetes-specific form of eating disorder which can have 
much sought after immediate effects but with serious short- and longer-term consequences.   
 
4.7.6.2. Weight reduction programs in NIDDM 
In NIDDM, obesity is more prevalent  than in the general population. Dietary therapy is the 
mainstay of treatment of NIDDM. A significant proportion of people who follow the dietary 
recommendations will regain metabolic control without having to take oral hypoglycemic tablets 
or insulin injections. In the overweight, calorie restriction is particularly important for metabolic 
control and weight loss is associated with improved glycemic control. Many studies have shown 
that it is possible to induce weight loss in NIDDM patients using a variety of pharmaceutical 
methods, e.g. appetite suppressants, behavioral methods, exercise, conventional diets or very low 
calorie diets (VLCDs). However, longer term studies typically show that subjects lose weight for 
the first 6 months of a program and thereafter regain the weight (Wing & Anglin, 1996). The UK 
Prospective Diabetes Study Group (1990) examined the responses of more than 3000 newly 
diagnosed NIDDM patients to diet therapy and showed that 16% achieved near-normal fasting 
glucose  after 3 months (with an average weight loss of 8 kg). However in the second 3 months 
the blood glucose increased a little in spite of continued but decelerated weight loss. Metabolic 
control appears to be related more to calorie intake than body weight per se. This study shows 
the value of diet therapy in the successful management of NIDDM but the weight loss required 
for adequate diabetes control may be considerable and oral hypoglycemic agents may be needed 
as well. 
 
The evidence suggests that that even when dietary change is achievable in the short term, it is not 
sustainable at the same level over a longer period. Perhaps more attention needs to be given to 
developing diets which are more acceptable to the individual and, hence, more sustainable. Diets 
may be unacceptable for economic, psychological or cultural reasons. A diet that may be 
affordable and tolerable in the short term with the support of therapist and fellow patients on a 
weight loss program may be unsustainable without such support. There is marked individual 
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variation in weight loss achieved in weight loss programs. In one intervention study, outcomes 
varied from a weight loss of 29.5kg to a gain of 7.7kg from pre-treatment to follow-up (Wing, 
Epstein, Nowalk, Koeske & Hagg, 1985). An understanding of the reasons for the variability 
may well be helpful in determining how to improve the success rate. In particular, consideration 
of patients' preferences for different weight loss programs may be of value in facilitating 
successful weight loss. It is likely that a group program will suit some but not others and 
different kinds of exercise program will suit different people. It is important to bear in mind that 
a conventional randomized clinical trial of particular weight-loss programs will have recruited 
only those individuals prepared to follow any of the programs under study and will be likely to 
have failed to recruit those patients with a strong preference for one program if the program (or a 
similar program) was available outside the trial. Where a new program is only available within a 
trial, the patients are likely to have marked preferences for that program, and disappointment will 
follow if randomization allocates the non-preferred treatment.  Subsequent responses, which may 
include dropping out of the trial, will undermine the assumptions of a randomized trial.  Such 
trials, attempting to answer the, perhaps inappropriate, question, 'Which weight loss program 
works best?' may be less useful in informing routine clinical practice than preference trials or 
partially-randomized preference trials, where patients with preferences are encouraged to follow 
the treatment they prefer and only those without preferences are invited to accept allocation of 
treatment by randomization. In such preference trials the question of interest is 'Which weight 
loss program works best for which patients?' (Bradley, 1993).  
 
Some studies have begun to look at reasons for success and failure in weight loss. National 
survey data in the USA were used to investigate self-reported weight loss and it was found that 
intentional weight loss in people with diabetes was associated with having been hospitalized 
twice in the previous year, and having seen a dietitian (Will, 1995) suggesting that a strong 
motivation to lose weight is important for success. Wing has shown that men lost weight faster 
than women but found no association between weight loss and whether or not subjects were 
taking insulin, nor between weight loss and duration of diabetes (Wing, Shoemaker, Marcus, 
McDermott & Gooding, 1990). Thus use of insulin and diabetes of long duration do not appear to 
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present particular obstacles to weight loss. In a later study, Wing and colleagues found smaller 
weight losses in blacks than whites related to faster regaining of weight in blacks (Wing & 
Anglin, 1996). Pierce and Armstrong (1996) found that in Afro-Caribbean diabetic patients the 
prescribed diets were held in contempt and largely ignored as being so mean as to be 
incompatible with a healthy life. Moreover the subjects profoundly disagreed with the medical 
notion of a healthy body weight. Large body size was perceived as healthy and  attractive within 
this group and valued as such. 
  
  
4.7.7. Treatment of Sexual Dysfunction 
 
The vascular and neuropathic complications of diabetes are associated with a higher incidence of 
sexual problems among men with diabetes than among non-diabetic men. Women with diabetes 
may also experience more sexual difficulties than non-diabetic women though not all studies 
have found differences between women with and without diabetes (Jensen, 1981). It has been 
erectile failure in men with prevalence of 35-59% (Bancroft & Gutierrez, 1996) which has 
attracted the attention of clinicians, researchers and pharmaceutical companies. The potential 
contribution of psychologists in dealing with the sexual problems of men with diabetes have 
been little recognized. The increased likelihood of an organic component to erectile dysfunction 
associated with diabetes has led to a disproportionate emphasis on drug (self-administered 
papaverine injections to induce erection), mechanical (vacuum tumescence), and surgical 
interventions (penile implants) vigorously promoted by the manufacturers. Although diabetic 
men are at least, if not more, likely than other men to have impotence of psychogenic origins, the 
ready availability of funding for trials of drug and surgical interventions has encouraged and 
facilitated such approaches while funding for trials of psychological therapies is far less readily 
available and such studies are few and far between. Nevertheless, there is evidence that good 
results can be achieved with psychological approaches. Veves, Webster, Chen, Payne & Boulton 
(1995) reported that psychosexual counseling resulted in successful intercourse in 17 (60%) of 
the 24 men opting for this treatment. A further 7 (25%) in whom the marital relationship had 
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previously been unstable, went on to medical treatment after marital therapy. The success rate for 
psychosexual interventions compared favorably with the success rate of (55%) for those opting 
for papaverine injections and did not have the unwanted consequences experienced by 15% of 
men using papaverine which included priapism, pain at injection site, and dizziness. However, 
the modest success rates of psychosexual counseling with unselected patients reported by 
McCulloch, Hosking & Tobert (1986), have been widely quoted as reason for pursuing 
biomedical approaches to treatment. Increasing experience of the failure of surgical implants and 
complications following surgery have led to the cautious view that surgery should be viewed as a 
'last resort' (Alexander, 1990; Dunsmuir & Holmes, 1996). Furthermore there is increasing 
emphasis on the importance of psychosexual counseling prior to biomedical interventions 
(Dunsmuir & Holmes).  
 
Several authors have noted an unwillingness among their patients to view their erectile 
dysfunction as psychogenic in origin, and the limited enthusiasm for psychosexual counseling 
(Alexander, 1990; McCulloch et al.1996; Veves, et al. 1995). How much of this resistance is due 
to physicians' emphasis on biomedical approaches and limited appreciation of psychological 
approaches is unclear. An editorial in the British Medical Journal recommended that patients 
with erectile impotence "should be told that impotence in diabetes has a physical cause and will 
not improve without a physical treatment" (Price, 1993). Others have taken issue with this view 
(Bancroft & Gutierrez, 1996),  but it is clear that this widespread exclusive focus on erectile 
dysfunction as an organic problem in diabetes will present a challenge to those wishing to 
encourage psychological approaches.  
 
Meisler, Carey, Lantinga & Krauss (1989) have offered guidelines for a multidisciplinary 
approach to assessment of sexual dysfunction. Further development and wider use of 
psychological interventions has the potential for improved psychosexual functioning and 
prevention of the often irreversible complications of biosurgical interventions.  
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4.8. CULTURAL ISSUES  
 
Cultural issues have been referred to at various points throughout the chapter along with life 
span, age and gender issues where each has been particularly relevant. Sections of the chapter 
concerned with risk factors for diabetes review evidence showing diabetes to be less common in 
white western populations than in other populations. The high incidence of diabetes among racial 
minorities in Western society present particular challenges to diabetes care services when 
language barriers pose particular problems of management for a disorder which requires complex 
self-management tasks and dietary change. Good communication between health professionals 
and their patients is central to the development of self-management skills and appropriate 
practical solutions need to be found to facilitate communication across languages with multi-
lingual health professionals or use of translators familiar with diabetes and its management. 
Clashes between cultural beliefs, lifestyle and recommendations for diabetes management, 
especially dietary recommendations, create particular difficulties where weight reduction is an 
important component of the recommended management plan for overweight people with 
NIDDM (see section 4.7.6). 
 
 
4.9. PROFESSIONAL ISSUES  
 
In the USA, involvement of psychologists in diabetes care teams is now standard practice. In the 
UK it is becoming increasingly common to find psychologists attached to diabetes care teams for 
two or more sessions per week although this is still the exception rather than the rule. A recent 
Briefing Paper from the British Psychological Society (British Psychological Society, Division 
of Clinical Psychology, 1994) on services for people with diabetes mellitus recommended one 
whole time equivalent post for each local diabetes service allocated between adult services, 
services to the elderly and services to children and young people. It was recognized that clinical 
psychologists who work with adults will not normally have the skills and knowledge to work 
effectively with children and their families and that special expertise may also be required for 
 
 
 
 
50 
some older people. Such recommendations are realistic rather than ideal. This level of input is 
likely to be mostly taken up with crisis intervention and problem solving rather than preventive 
work to improve communication, knowledge and skills in diabetes management across the 
service as a whole which in the longer term would be of most benefit. 
 
There is considerable scope for clinical psychologists to make valuable contributions to diabetes 
management, providing assessment and treatment and conducting research and evaluation as well 
as teaching other health professionals and patients. Several specific psychological therapies 
which clinical psychologists may be able to offer include stress management and relaxation 
training, weight management interventions and management of eating disorders and sexual 
dysfunction. More general psychological skills will be valuable in helping patients to identify 
and overcome barriers to self care and in facilitating the process of helping patients and their 
advisors to negotiate manageable treatment regimens which are tailored to individuals' lifestyles 
and preferences. 
 
For clinical psychologists to be most effective in diabetes care, detailed understanding is required 
of diabetes and the varieties of management possible. The management regimens recommended 
in a particular clinic are likely to be only a small minority of those which could be made 
available. There are many diabetologists who continue to recommend particular doses and timing 
of insulin which then dictate the timing of meals and snacks and require patients to manipulate 
their diet and exercise to fit in with the regimen prescribed. Initially it may well be more 
demanding to teach patients how to manipulate their insulin appropriately to fit in with preferred 
meal times and varying levels of energy expenditure but in the longer term it is a great deal less 
demanding and more convenient for the patient, their family, friends and other associates if they 
adjust their insulin dose rather than their life (Howorka, 1996). Problems with poor diabetes 
control which diabetologists may construe as 'compliance' problems may more productively be 
construed as inflexible treatment recommendations and/or inadequate education in diabetes 
management and self-care skills in adjusting insulin doses and timing to accommodate a flexible 
lifestyle. By developing an understanding of how diabetes can be managed physiologically and 
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by appreciating the range of different medical approaches to diabetes management, clinical 
psychologists are better placed to apply their psychology to the task of improving diabetes 
management while at the same time protecting, and even improving, the psychological well- 
being and quality of life of people with diabetes.
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Table 1 WHO (1985) Classification of Diabetes Mellitus  
 
1. Insulin-dependent diabetes mellitus (IDDM) 
2. Non-insulin-dependent diabetes mellitus (NIDDM) 
 a. Non-Obese 
 b. Obese 
3. Malnutrition-related disorders 
4. Other types of diabetes associated with certain conditions and syndromes including:  
 pancreatic disease; diseases of hormonal etiology; drug induced or chemical-induced 
 conditions; abnormalities of insulin or its receptors; certain genetic syndromes. 
5. Gestational diabetes mellitus 
 
NIDDM and IDDM are the most common forms of diabetes in first-world countries with 
gestational diabetes also being common. 
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